Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.97 USD | +0.02% | -2.36% | -14.32% |
05-14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
Sales 2024 * | 512M 699M | Sales 2025 * | 627M 856M | Capitalization | 3.4B 4.65B |
---|---|---|---|---|---|
Net income 2024 * | -560M -765M | Net income 2025 * | -476M -650M | EV / Sales 2024 * | 6.11 x |
Net cash position 2024 * | 274M 374M | Net cash position 2025 * | 337M 460M | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
-6.24
x | P/E ratio 2025 * |
-7.83
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.9% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | +0.02% | ||
1 week | -2.36% | ||
Current month | -3.69% | ||
1 month | -12.83% | ||
3 months | -10.27% | ||
6 months | +6.97% | ||
Current year | -14.32% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | -2.17% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 40.97 | +0.02% | 558,167 |
24-05-13 | 40.96 | +0.15% | 440,612 |
24-05-10 | 40.9 | -0.78% | 549,642 |
24-05-09 | 41.22 | -0.82% | 407,732 |
24-05-08 | 41.56 | -0.95% | 764,567 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.32% | 3.4B | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- RARE Stock